Build a lasting personal brand

Nutriband Secures USPTO Notice of Allowance for Brand Names of Abuse-Deterrent Fentanyl Patch

By Burstable Editorial Team•
Nutriband received a USPTO Notice of Allowance for trademarks covering its lead abuse-deterrent fentanyl transdermal system, advancing the product toward regulatory review and potential commercialization.
Nutriband Secures USPTO Notice of Allowance for Brand Names of Abuse-Deterrent Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB) announced that it received a Notice of Allowance dated Nov. 3, 2026, from the United States Patent and Trademark Office for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company intends to pursue full trademark registration in the United States and internationally and is preparing to submit its proposed global brand name to the U.S. Food and Drug Administration, European Medicines Agency and other regulatory authorities for preapproval review. Nutriband said its naming process emphasizes minimizing potential medication errors associated with similar-looking or similar-sounding drug names.

The company’s lead product incorporates its proprietary AVERSA technology, designed to deter intentional abuse and misuse of fentanyl patches while reducing accidental exposure risks. Nutriband estimates potential peak annual U.S. sales of $80 million to $200 million for the product and is pursuing development for international markets. Its AVERSA technology uses aversive agents in transdermal patches to discourage misuse of medications with abuse potential, including opioids and stimulants, and is supported by patents issued in 46 countries. To view the full press release, visit https://ibn.fm/FN3Or.

The Notice of Allowance is a significant milestone for Nutriband as it moves toward commercializing its abuse-deterrent fentanyl patch. Securing brand name protection is a critical step in the pharmaceutical development process, helping to ensure product identity and reduce the risk of medication errors once the product reaches the market. The company’s proactive approach to global trademark registration and regulatory preapproval submissions underscores its commitment to a coordinated international launch strategy.

For investors, the announcement highlights progress on a product with substantial peak sales potential. The estimated $80 million to $200 million in annual U.S. sales reflects the company’s confidence in the market opportunity for a safer fentanyl patch. The global patent coverage across 46 countries further strengthens the product’s competitive position and supports Nutriband’s expansion plans.

The development also has implications for the broader fight against opioid abuse. Fentanyl patches are effective for pain management but carry risks of misuse and accidental exposure. AVERSA technology aims to address these risks by incorporating aversive agents that discourage abuse without compromising therapeutic benefits. If approved, the product could provide a safer option for patients and healthcare providers.

Nutriband’s progress was reported by BioMedWire, a communications platform focused on biotechnology and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. For more information, visit www.nutriband.com.

Burstable Editorial Team

Burstable Editorial Team

@burstable

Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.